Dr. Rubenstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
400 Parnassus Ave
San Francisco, CA 94143Phone+1 415-353-2421Fax+1 415-353-2467
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1994 - 1997
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1992 - 1995
Weill Cornell MedicineClass of 1992
Certifications & Licensure
CA State Medical License 1994 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma Start of enrollment: 2004 Oct 01
- A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma Start of enrollment: 2007 Apr 01
- Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma Start of enrollment: 2003 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 112 citationsA Systematic Approach to the Diagnosis of Suspected Central Nervous System LymphomaBrian J. Scott, Vanja C. Douglas, Tarik Tihan, James L. Rubenstein, S. Andrew Josephson
JAMA Neurology. 2013-03-01 - 153 citationsDiffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma.Ramon F. Barajas, James L. Rubenstein, Jamie S. Chang, Jimmy Hwang, Soonmee Cha
AJNR. American Journal of Neuroradiology. 2010-01-01 - 72 citationsConsensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collabora...Ramon F. Barajas, Letterio S. Politi, Nicoletta Anzalone, Heiko Schöder, Christopher P. Fox
Neuro-Oncology. 2021-07-01
Abstracts/Posters
- Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy StudiesJames L. Rubenstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Understanding the Role of Autologous Transplant and Consolidation Strategies: Opinions and OptionsASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
Other
- AIDS-related lymphomas: Primary central nervous system lymphomaRubenstein JL, Kaplan LD
http://www.uptodate.com/contents/aids-related-lymphomas-primary-central-nervous-system-lymphoma
UpToDate, Wolters Kluwer Health - 2012-07-16
Press Mentions
Lenalidomide Highly Effective in Early Phase CNS Lymphoma StudyJune 20th, 2015
Grant Support
- The Role Of Interleukin-4 (Il-4) In The Pathogenesis Of Non-Hodgkin'S LymphomaNational Cancer Institute2009–2011
- Molecular Classification And Therapy Of CNS LymphomasNational Cancer Institute2004–2008
- Intrathecal Rituximab In Patients With Recurrent Lymphomatous MeningitisNational Center For Research Resources2004
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
